Vincent Pham Recognized as a 2026 SynBioBeta Next-Gen BioLeader

SAN ANTONIO, Texas — The Huang Lab at the Mays Cancer Center at UT Health San Antonio announces that Vincent Pham, Cancer Biology PhD Candidate and Co-Founder and CEO of Powerhouse Therapeutics, has been recognized as a 2026 SynBioBeta Next-Gen BioLeader. The program highlights emerging leaders shaping the future of synthetic biology.

Vincent is attending SynBioBeta to connect with synthetic biology leaders and share what Powerhouse Therapeutics is building. His conversations center on the IT-ACTS platform, which pairs tumor-targeting cell therapy with engineered signals designed to remodel the tumor immune microenvironment. The platform reflects a programmable, engineering-first approach to cell and gene therapy.

"Synthetic biology gives us a vocabulary for designing therapies rather than discovering them one molecule at a time," said Vincent. "It is energizing to compare notes with leaders who think about biology as something we can engineer with intent."

About the Huang Lab

The Huang Lab at UT Health San Antonio is a basic and translational cancer research group within the MD Anderson Mays Cancer Center at UT Health San Antonio. Our team integrates hematology and solid tumor biology with immunology and metabolism to uncover mechanisms and design interventions. We advance cell and biologic therapies, including CAR T-cell approaches for solid tumors. We also conduct research in trauma and military health. We move discoveries toward clinical impact through product development and collaborations with clinicians and industry. Education and mentorship are core to our mission. We train students, postdoctoral fellows, and early-career scientists in rigorous, multidisciplinary research. Together, we aim to deliver therapies and technologies that improve patient outcomes.